Sunday , 19 January 2025
0

No products in the cart.

Worldwide News Worldwide News
0

No products in the cart.

Home Health AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition
Health

AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition

October 29, 20241 Mins read31 Views
AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition

Aliada brings AbbVie an early clinical Alzheimer’s disease drug candidate as well as the platform technology that produced it. Aliada licensed its brain delivery technology from Johnson & Johnson.

The post AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition appeared first on MedCity News.

Previous post ECB's De Guindos: Price outlook surrounded by substantial risks

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Health

AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of...

ByJanuary 17, 2025

This interactive chart allows users to track public opinion on the Affordable...

ByJanuary 17, 2025
Health

By MIKE MAGEE In case you’ve missed it, sleep is all the...

ByJanuary 17, 2025
Health

Teladoc Health has joined Amazon’s Health Benefits Connector. Other companies offered through...

ByJanuary 17, 2025

Abous us

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis

Subscribe Now

    Subscribe to our mailing list to receives daily updates direct to your inbox!
    © Copyright 2022 Jellywp. All rights reserved powered by Jellywp.com